Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma-Reference-Cited by-同舟云学术

Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma

Published:2020-03-04 Issue:13 Volume:63 Page:6648-6676
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Hansen Joshua D.¹^ORCID,Correa Matthew¹,Nagy Mark A.¹,Alexander Matt¹,Plantevin Veronique¹,Grant Virginia¹,Whitefield Brandon¹,Huang Dehua¹,Kercher Timothy¹,Harris Roy¹,Narla Rama Krishna¹,Leisten Jim¹,Tang Yang¹,Moghaddam Mehran¹,Ebinger Katalin¹,Piccotti Joseph¹,Havens Courtney G.¹,Cathers Brian¹,Carmichael James¹,Daniel Thomas¹,Vessey Rupert¹,Hamann Lawrence G.¹^ORCID,Leftheris Katerina¹,Mendy Derek¹,Baculi Frans¹,LeBrun Laurie A.¹,Khambatta Gody¹,Lopez-Girona Antonia¹

Affiliation:

1. Celgene Corporation, 10300 Campus Point Drive, Suite 100, San Diego, California 92121, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b01928

Reference22 articles.

1. American Cancer Society, Cancer Statistic Center Page. https://cancerstatisticscenter.cancer.org/?_ga=2.200904942.1379280727.1580495928-1064148705.1580495928#!/cancer-site/Myeloma (accessed Jan 2020).

2. Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update

3. Identification of a Primary Target of Thalidomide Teratogenicity

4. Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

5. The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

Cited by 146 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunomodulation and anticancer evaluation of quinazoline-based thalidomide analogs: Design, synthesis, docking, and dynamic simulation;Journal of Molecular Structure;2024-12

2. Inducing or enhancing protein-protein interaction to develop drugs: Molecular glues with various biological activity;European Journal of Medicinal Chemistry;2024-11

3. Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation;Journal of Hematology & Oncology;2024-09-02

4. Asymmetric Dirhodium-Catalyzed Modification of Immunomodulatory Imide Drugs and Their Biological Assessment;ACS Medicinal Chemistry Letters;2024-08-23

5. Targeted protein degradation in hematologic malignancies: clinical progression towards novel therapeutics;Biomarker Research;2024-08-21